Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others


FDA approves second indication for SKYRIZI®

The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.

Read More

European Commission approves SKYRIZI® for psoriatic arthritis in adults

The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.